Allakos is Crashing today, Tests Failed Allokos said that lirentelimab failed to meet co-primary endpoints in two clinical studies.
Shares of Allakos (NASDAQ: ALLK) are crashing 88% lower as of 10:17 a.m ET on Wednesday. The huge decline came after...